Abstract:In the past few years the medical treatment of malignant diseases has steadily increased in scope and importance. However, the tumor regimens described in the textbooks still are rather schematic recommendations, which are inadequately tailored to the needs of the individual case. Current tumor therapy is based on the results of the statistical analysis using empirical data collected in randomized trials. While patients can today be given a statistical value which expresses their computed chance of a cure versus that of a defined population, there is still no generally valid method which could serve as a rational basis for individualized counselling. But cytostatic chemotherapy has yet another major shortcoming: the collective assessment of toxicity, which is related to one of the basic properties of cytostatic drugs, i.e. their extremely low therapeutic index. Many of the side effects of cytostatics may cause severe irreversible, at times even fatal, organ dysfunction. Consequently, the definition of the therapeutic risks involved on the basis of an objective identification of potential organ toxicity is a major challenge. "Surgery without a knife", as K.H. Spitzy has called chemotherapy, should be subjected to objective criteria for its indications and contraindications so that patients can truly benefit from what are become increasingly aggressive measures. The principle of weighing the benefits desired in the individual case against the potential risks involved in a specific treatment, which Paul Ehrlich postulated for antibacterial chemotherapy, should also be applied to cytostatic chemotherapy with a view to facilitating the decision for or against therapy in borderline cases. The present contribution which is designed to shed light on the cardiotoxicity of doxorubicin should be interpreted in light of this situation. Pathogenetic aspects and animal experiments on drug-induced lipid peroxidation will be discussed and clinical trials on both acute and chronic doxorubicin cardiotoxicity will be reviewed. Special attention will be paid to the tolerable risks of this special form of toxicity and cardiologic methods currently available for patient monitoring will be critically assessed. In summary, the studies produced the following results: A. Pathogenesis Treatment of C 57 B1 mice with doxorubicin increases the production of malonic dialdehyde in the myocardium. Enhanced malonic dialdehyde production can largely be suppressed by the additional administration of anti-oxidants (tocopherol, glutathione, cysteamine, cysteine).(ABSTRACT TRUNCATED AT 400 WORDS)

Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?

Anthracycline Cardiotoxicity: From Mechanisms to Prevention Strategies

A Review on Anthracycline Induced Cardiotoxicity- A Mechanism-based Approach

[Cardiotoxicity of drugs used in oncology]

Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity

Magnesium hexacyanoferrate nanocatalysts attenuate chemodrug-induced cardiotoxicity through an anti-apoptosis mechanism driven by modulation of ferrous iron

Anthracycline Chemotherapy and Cardiotoxicity

Cardiotoxicity of doxorubicin – causes, prevention, prospects

Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients

Anthracycline-induced cardiotoxicity: An overview from cellular structural perspective

Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors

Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management

Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury

Recent advances in the prevention of anthracycline cardiotoxicity in childhood

An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity

Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer?

Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions

Precision Treatment of Anthracycline-Induced Cardiotoxicity: An Updated Review

Epigenetic Changes Associated With Anthracycline-Induced Cardiotoxicity

Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity

[Selective toxicity of cytostatic agents: studies on the cardiotoxicity of doxorubicin, its pathogenesis and contraindications]